Pipeline news

• Clearside Biomedical Appoints Viral Kansara as Vice President, Discovery

  12 September 2018

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Viral Kansara, Ph.D. to the position of Vice President, Discovery. 

• Clearside Biomedical Appoints Accomplished Pharmaceutical Industry Legal Executive, Leslie Zacks, as General Counsel and Chief Compliance Officer

  11 September 2018

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of  Leslie Zacks  as General Counsel and Chief Compliance Officer.

• Researchers provide compelling evidence for multiple STI-detecting device

  11 September 2018 St. George's University of London / Medical Xpress

  

  Using mathematical modelling, researchers within the Applied Diagnostics Research and Evaluation Unit at the university concluded that a bespoke point-of care diagnostic device could significantly reduce the number of return clinical visits and the average time-to-cure from about a week to one day. The device is in early phases of development by Atlas Genetics Limited, following a grant from from Innovate UK via the Small Business Research Initiative.

• Clearside Biomedical Further Strengthens Commercial Organization With Appointment of Lester Rodríguez as Vice President, Quality

  06 September 2018

  

  Clearside Biomedical, Inc. (NASDAQ: CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Lester Rodríguez as Vice President, Quality.

• Marinus Appoints Scott Braunstein, MD to its Board of Directors

  05 September 2018

  

  Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the appointment of Dr.  Scott Braunstein  to its Board of Directors. Dr. Braunstein brings over 20 years of knowledge and experience from diverse biotechnology and pharmaceutical industry vantage points.

• Epic Sciences Appoints Katherine Atkinson as Chief Commercial Officer

  04 September 2018

  

  Epic Sciences (Epic), the maker of the world’s first predictive test of drug response in prostate cancer, announced the expansion of its leadership team with the appointment of Katherine Atkinson as chief commercial officer. In this new role, Atkinson will be responsible for the development of Epic’s global commercial strategy by identifying new strategic business opportunities and deepening its existing strategic partnerships.   

• Blood Test Can Identify Patient Response to Prostate Cancer Treatments

  17 August 2018 Jennifer Barrett / Specialty Pharmacy Times

  A blood test can help detect whether patients with advanced prostate cancer will respond to a certain treatment, according to a new study. This approach could help better inform the choice of therapy and lead to improved outcomes. In the study, researchers used a liquid biopsy test developed by Epic Sciences to examine circulating tumor cells (CTCs) in blood samples from 142 patients with advanced prostate cancer deciding whether to switch from hormone-targeting therapy to chemotherapy.

• Clearside Biomedical Announces Second Quarter 2018 Financial Results and Provides Corporate Update

  08 August 2018

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today reported financial results for the quarter ended  June 30, 2018  and provided an update on its development programs.

• Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update

  07 August 2018

  

  Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the second quarter ended  June 30, 2018 . In addition, the Company provided a clinical and business update. As of  June 30, 2018 , Syndax had  $98.4 million  in cash, cash equivalents and short-term investments.

• Marinus Pharmaceuticals Provides Business Update and Second Quarter 2018 Financial Results

  02 August 2018

  

  Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the second quarter ended  June 30, 2018 .